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Use of active vitamin D sterols in patients with chronic kidney With current interest in various pharmacologic and nutri-
disease, stages 3 and 4. This paper reviews randomized con- tional approaches aimed at slowing the progression of
trolled trials and other reported data on the use of the active CKD toward end-stage renal disease (ESRD), attentionvitamin D sterols, such as calcitriol, alfacalcidol, and doxercal-
toward the management of secondary hyperparathyroid-ciferol, in the management of secondary hyperparathyroidism
ism is indicated to minimize the development of progres-in patients with mild-to-moderate renal insufficiency (stage 3 or
4 chronic kidney disease). Data on potential benefits, including sive bone disease.
improved histologic abnormalities of bone from secondary hy- This review considers the benefits and potential pitfalls
perparathyroidism, increased bone mineral density, and a re-
of therapy of secondary hyperparathyroidism with theduction of elevated parathyroid hormone levels, are docu-
active vitamin D sterols. The nomenclature used is thatmented. Consideration is given to the risks of such therapy,
which include the production of hypercalcemia, more rapid recommended by the National Kidney Foundation [1].
progression of renal insufficiency, the induction of adynamic We focus on patients with CKD, stage 3: glomerular
bone “disease,” and accelerated vascular and soft tissue calcifi- filtration rate (GFR) 30 to 59 mL/min/1.73m2; and stagecation. The low therapeutic index, or “benefit/risk ratio” of
4: GFR, 15 to 29 mL/min/1.73m2. The treatment of pa-calcitriol and alfacalcidol, the sterols currently licensed for such
tients with stage 5 CKD (those with a GFR 15 mL/treatment, is recognized. It is recommended that phosphate-
restricted diets, phosphate-binding agents, and oral calcium min/1.73m2 or undergoing dialysis) is not included.
supplements be given adequate trials before starting calcitriol Calcitriol and alfacalcidol have been in use for more
or alfacalcidol. If PTH levels cannot be controlled by these
than three decades, and several “new” active analogs ofmeasures, initial doses of these sterols and the proper surveil-
vitamin D are now available [2]. A recommendation willlance during treatment are given. It is emphasized that the
risks of hypercalcemia are likely to increase as the degree be made when patients with CKD should be considered
of kidney failure worsens. Further research using the “less for treatment with an active vitamin D sterol, with rec-
calcemic” vitamin D sterols is clearly needed. ommendations on initial dosages.
In this review, more weight will be given to random-
ized controlled trials (RCT), but lessons learned from
Secondary hyperparathyroidism appears and advances open-label experiences will also be considered. There
with progressive deterioration of renal function that is are reports on the use of active vitamin D sterols in
common with chronic kidney disease (CKD). There is patients with stage 3 or 4 CKD in 8 RCTs [3–10] and
evidence, which is reviewed elsewhere in this issue, that several controlled open-label trials [11–15].
the renal synthesis of calcitriol is impaired as kidney
function is reduced, and this contributes to the develop-
BENEFITS OF THERAPYment of secondary hyperparathyroidism. Also, in pa-
tients with CKD, both inadequate dermal synthesis and Three of the earliest studies reported that calcitriol
reduced intake of vitamin D per se, as evidenced by led to substantial improvement of skeletal histomorpho-
suboptimal plasma 25(OH)-vitamin D levels is common; metry from the pre- to posttreatment bone biopsies [3–5];
this “vitamin D insufficiency” predisposes such patients however, the PTH measurements used immunoassays
to the development of secondary hyperparathyroidism. that cannot be readily compared with the widely used
“second generation” intact PTH assay. Moreover, most
CKD patients entered these trials independent of the
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PTH level. Bianchi et al [12] did find skeletal histomor-doxercalciferol, mild to moderate renal insufficiency, treatment, guide-
lines, bone density, hypercalcemia. phometric features of significant secondary hyperpara-
thyroidism in their CKD patients who had “second gen- 2003 by the International Society of Nephrology
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eration” intact PTH levels that were only modestly only 0.125 g/day for one year to patients with serum
creatinine levels of 1.4 to 6.5 mg/dL. Serum Ca and Pelevated, with a mean value of about twice the upper
normal limit. Creatinine clearances ranged from 36 to levels were unchanged with calcitriol treatment, and in-
tact PTH levels did not fall. However, intact PTH levels64 mL/min, indicating that most patients had stage 3
CKD. The second bone biopsies, done after two years of rose in the placebo-treated patients. The changes of in-
tact PTH during treatment with calcitriol versus placebotreatment with calcitriol 0.25 g/day, showed significant
improvement. This study [12] is of note in that there was were most evident in patients with higher entry serum
creatinine levels (3.0 mg/dL). In an RCT using doxer-little or no histologic evidence for “skeletal resistance”
to PTH action, as was found in bone biopsies from hemo- calciferol (1D2), the initial dose of 1.0 g/day was in-
creased at intervals if the intact PTH was not lowereddialysis patients [16, 17], and in those with stage 5 CKD
who had not yet initiated dialysis [18]. In the large RCT by 30%, and provided the serum calcium was below 9.6
mg/dL and serum P below 4.6 mg/dL [10]. During theof Hamdy et al [8], abnormal bone histology was found
in 73% and 76% of patients with mean entry intact PTH six-month RCT, mean intact PTH fell by 46% in 1D2-
treated patients who exhibited a maximum increase oflevels of 68 and 109 pg/mL in placebo and alfacalcidol
groups, respectively. Of the alfacalcidol-treated patients mean serum calcium of 0.4 mg/dL. Levels of intact PTH
were unchanged in the placebo group; also, serum Cawith abnormal bone histology on the entry bone biopsy,
42% were normalized after two years of treatment, com- and P did not differ significantly between the placebo
and doxercalciferol groups. The average dose of 1D2pared to only 4% of patients assigned to placebo. An-
other benefit of active vitamin D treatment has been was 1.6 g/day at the end of the six- month trial.
improvement of bone mineral density (BMD) [6, 9, 12].
Compared to changes in BMD measurements over six
ADVERSE EFFECTS
months prior to treatment, Bianchi et al [12] found slow-
A major concern about the use of active vitamin Ding of bone loss in the forearm and spine following 24
sterols is the occurrence of hypercalcemia. In the earlymonths of calcitriol treatment 0.25 g/day. In an RCT,
trials with calcitriol, daily dosages were increased fromPrzedlacki et al [6] found significant improvement of
0.25 to 0.50 g [4, 5], or even to 0.75 g [3]; the higherBMD of the lumbar spine and femoral neck after treat-
doses led to unacceptable rises of serum Ca that necessi-ment for one year with calcitriol, 0.25 g/day, compared
tated a dose reduction in most patients. In subsequentto the placebo group. In an 18-month placebo-controlled
RCTs and in open-label studies, hypercalcemia was un-trial, Rix [9] found improved BMD of the spine and
usual with the use of calcitriol in doses that did notfemur in CKD patients given alfacalcidol compared to
exceed 0.25 g/day [6, 11, 12], and with alfacalcidol inthe placebo group; the alfacalidol dose averaged 0.44
doses of 0.25 to 0.5 g/day [8]. In the two-year study ofg/day.
Hamdy et al [8] that included 89 alfacalcidol-treatedAnother finding during treatment with an active vita-
patients, serum Ca exceeded 12.0 mg/dL in four patientsmin D sterol is a significant reduction of elevated PTH
and reached 10.5 to 12.0 mg/dL in 10 alfacalcidol patients,levels in comparison to those receiving placebo [6–10, 12].
compared to three of 87 placebo patients. Bianchi et alThe degree of reduction of PTH differed depending on
[12] found mean serum Ca 8.5  0.3 (SE) at baselinethe dosages used, the duration of treatment, and the
and 9.3  0.2 and 9.9  0.2 mg/dL after treatment forchanges of serum calcium. Hamdy et al [8] gave alfacalci-
12 and 24 months, respectively; the incidence of hyper-dol at a starting dose of 0.25 g/day and increased the
calcemia was not reported. A risk of hypercalcemiadose if serum Ca did not increase “slightly” within the
would most likely be greater in patients given vitamin Dnormal range; they noted a maximum reduction of intact
sterols in the less structured follow-up of clinical practice.PTH at six months, followed by a slow increase to base-
The occurrence of hypercalcemia would be more com-line at the end of two years of treatment with a mean
mon as renal function decreases and there is less abilityalfacalcidol dose of 0.42 g/day. In contrast, intact PTH
of the diseased kidney to excrete additional calcium.levels rose progressively in the placebo-treated patients
In the placebo-controlled trials, serum P levels wereover two years. The mean serum Ca level rose by approx-
either unchanged or rose slightly with time in the studiesimately 0.4 mg/dL with alfacalcidol and was unchanged
of longer duration, as renal function decreased in bothwith placebo [8]. With calcitriol 0.25 g/day, combined
treated and placebo patients [8, 19]. There were no dif-with supplemental calcium carbonate providing calcium
ferences between those receiving placebo or the active400 mg/day, Bianchi et al [12] noted mean reductions of
vitamin D sterol.intact PTH by 35% and 42% after 12 and 24 months,
Another potentially adverse event would be the con-respectively. These changes of intact PTH occurred in
version of bone disease to adynamic, or low-turnoverassociation with significant increments of mean serum
bone “disease.” In the RCT of Baker et al [5] that utilizedCa of 0.8 and 1.4 mg/dL at these periods, respectively.
In an RCT, Ritz et al [7] gave calcitriol in a dose of calcitriol in seven patients at doses up to 0.50 g/day,
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Table 1. Recommendations for therapy with active vitamin D sterol in CKD, stage 3a
Measure intact PTH
If 70 pg/mL, monitor patient and maintain S-Ca 8.8 to 9.5 mg/dL and S-P 3.0 to 4.6 mg/dL
If 70 pg/mL, follow next guideline
If S-Ca 9.5 mg/dL despite supplemental Ca and S-P 4.6 mg/dL and iPTH 70 pg/mL, reduce dietary P and/or increase dose of
phosphate-binders
After 3 months, if intact PTH remains 70 pg/mL and S-Ca 9.5 pg/mL and S-P 3.0 to 4.6 mg/dL, initiate active vitamin D sterol, calcitriol,
or alfacalcidol 0.25 g/dayb
Follow S-Ca, S-P monthly
S-Ca 9.5 mg/dL, lower Ca-based P-binder dose or vitamin D dose
S-P 4.6 mg/dL, reduce P intake and/or raise P-binder dose
If S-P remains 4.6 mg/dL, reduce or stop vitamin D
Follow intact PTH levels quarterly
If PTH 70 pg/mL, maintain and/or resumec active vitamin D
If PTH 35 pg/mL, stop active vitamin D
If PTH 35 to 50 pg/mL, reduce active vitamin D dose
Follow S-Ca, S-P, and PTH
Manage using same parameters noted above
a If serum 25(OH)-vitamin D level 30 ng/mL, give supplemental vitamin D2 or D3
b Vitamin D sterols approved for treating secondary hyperparathyroidism in CKD, stages 3 and 4
c After vitamin D is stopped for high S-P or S-Ca, or low PTH, the dose should be reduced
Table 2. Recommendations for therapy with active vitamin D sterol in CKD, stage 4a
Measure intact PTH
If 110 pg/mL, monitor patient: maintain S-Ca 8.8 to 9.5 mg/dL and S-P 3.0 to 4.6 mg/dL
If 110 pg/mL, follow next guideline
If S-Ca 9.5 mg/dL despite supplemental Ca and S-P 4.6 mg/dL AND iPTH 110 pg/mL, reduce dietary P and/or increase dose of
phosphate-binders
After 3 months, if intact PTH remains 110 pg/mL and S-Ca 9.5 pg/mL and S-P 3.0 to 4.6 mg/dL, initiate active vitamin D sterol, calcitriol,
or alfacalcidol 0.25 g/dayb
Follow S-Ca, S-P monthly
S-Ca 9.5 mg/dL, lower Ca-based P-binder dose or vitamin D dose
S-P 4.6 mg/dL, reduce P intake and/or raise P-binder dose
If S-P remains 4.6 mg/dL, reduce or stop active vitamin D
Follow intact PTH levels quarterly
If PTH 85 pg/mL, maintain and/or resumec active level vitamin D
If PTH 70 pg/mL, stop active vitamin D
If PTH 70 to 85 pg/mL, reduce active vitamin D dose
a If serum 25(OH)-vitamin D level 30 ng/mL, give supplemental vitamin D2 or D3
b Vitamin D sterols approved for treating secondary hyperparathyroidism in CKD, stages 3 and 4
c After vitamin D is stopped for high S-P or S-Ca, or low PTH, the dose should be reduced
there was concern about the risk of excessive reduction 4 CKD patients when there are only small increments
of serum calcium.of bone formation leading to adynamic bone (H. Mal-
luche, personal communication, 2002). Bianchi et al did Another concern is whether treatment with an active
vitamin D sterol can cause impairment of renal function.not find adynamic bone after 24 months of treatment
with calcitriol 0.25 g/day. In the Hamdy study [8], nine With the use of calcitriol in doses of 0.5 g/day for four
months in 10 CKD patients, Bertoli et al [13] observedpatients had adynamic bone on the initial biopsy before
treatment; this disorder resolved in four of six alfacalci- increments of serum creatinine and reductions of creati-
nine clearance; however, GFR measured by inulin clear-dol-treated patients and two of three placebo patients.
After two years of treatment, eight of 72 alfacalcidol- ance did not change. Two months after calcitriol was
stopped, serum creatinine levels returned to baseline.treated patients had developed adynamic bone, com-
pared to four of 62 placebo-treated patients. In contrast Calcitriol can raise serum creatinine levels in individuals
with normal renal function, as well. Thus, small but sig-to the rarity of low bone turnover, adynamic bone was
found in 32% of 92 stage 5 CKD predialysis patients nificant increments of serum creatinine were noted in
both healthy, elderly women given calcitriol 0.5 g/daywho had bone biopsies at the time of vascular access
surgery [18]; these patients never received active vitamin for 12 months [20], and in psoriatic patients given
calcitriol 1.5 to 4.0 g each night [21]. In eight CKD andD sterols, indicating no relation between the develop-
ment of this lesion and vitamin D treatment. Thus, a risk psoriatic patients, inulin and creatinine clearances were
measured before and after six months of treatment; cre-of developing adynamic bone seems small in stage 3 and
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atinine clearance fell by 24%, but there was no change and the addition of phosphate-binding agents combined
with appropriate supplemental calcium intake. If iPTHin GFR as measured by inulin clearance [21]. These
observations are consistent with calcitriol in doses of 0.5 levels fall into the desirable range, treatment with an
active vitamin D sterol would not be necessary. The lowg/day and above, reducing the renal tubular secretion of
creatinine, but without affecting GFR. The retrospective therapeutic index of these potent active vitamin D sterols
must be recognized, and adequate follow-up of patientsobservations of Coen et al [19], who evaluated changes
of renal function utilizing the slope of 1/serum creatinine, entered into such treatment is essential. Further data
are needed to identify whether the “newer” vitamin Dindicate a reduced rate of progression of CKD in a sig-
nificant fraction of patients given calcitriol 0.25 g/day, sterols may be safer than calcitriol or alfacalcidol.
compared to CKD patients not given the vitamin D ste-
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Los Angeles, CA 90073.of 0.25 g/day, may not affect the tubular secretion of
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